Mirae Asset Global Investments Co. Ltd. Acquires 11,193 Shares of Repligen Corporation (NASDAQ:RGEN)

Mirae Asset Global Investments Co. Ltd. boosted its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 60.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,822 shares of the biotechnology company's stock after acquiring an additional 11,193 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.05% of Repligen worth $3,979,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. acquired a new stake in shares of Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG bought a new stake in Repligen in the fourth quarter valued at about $29,000. Itau Unibanco Holding S.A. acquired a new position in Repligen in the fourth quarter valued at about $40,000. Finally, Center for Financial Planning Inc. lifted its stake in Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 0.4%

NASDAQ RGEN traded up $0.52 on Wednesday, reaching $126.96. The company had a trading volume of 523,165 shares, compared to its average volume of 728,350. The company's fifty day moving average is $127.70 and its 200-day moving average is $140.50. The firm has a market capitalization of $7.13 billion, a price-to-earnings ratio of -282.13, a price-to-earnings-growth ratio of 3.56 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a 1-year low of $102.97 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. Repligen's revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 earnings per share. On average, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RGEN. Royal Bank Of Canada lowered their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Finally, Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a research note on Sunday. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $172.83.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.